Biogen and Ionis Pharma Shares Plummet Following Forsaken ALS Treatment Development

Thursday, 16 May 2024, 18:07

Biogen and Ionis Pharma have decided to discontinue the development of their ALS treatment following an unsuccessful early-stage trial that did not demonstrate effectiveness in slowing down the disease progression. The decision has led to a significant drop in the share prices of both companies, indicating investor concerns about the future prospects of the treatment and its potential impact on the companies' financial performance.

https://store.livarava.com/8911ab25-13af-11ef-a6c2-63e1980711b2.jpg — Biogen and Ionis Pharma Shares Plummet Following Forsaken ALS Treatment Development

Biogen and Ionis Pharma shares slide

The shares of Biogen and Ionis Pharma have taken a hit following their joint decision to cease the development of an ALS treatment, citing lack of efficacy in preliminary trials.

Reason for termination

The move comes after early-stage trial failed to result in a clear signal it slowed the disease process.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Biogen and Ionis Pharma shares slide

Reason for termination

Related posts